Mavacamten

The introduction of mavacamten represents a major shift in the treatment of obstructive hypertrophic cardiomyopathy, but raises dosing and drug-drug interaction challenges.

A new guideline on hypertrophic cardiomyopathy endorses the use of cardiac myosin inhibitors for certain patients with obstructive HCM and encourages exercise in all patients with HCM.

Compared with placebo, aficamten was associated with increased exercise capacity and improvements in symptoms of obstructive hypertrophic cardiomyopathy, according to topline results of the phase 3 SEQUOIA-HCM trial.

Bristol Myers Squibb announced that the FDA has approved updated labeling for mavacamten to reflect positive data from the VALOR-HCM trial.

Mavacamten improved a range of cardiopulmonary exercise testing parameters beyond peak oxygen uptake in patients with obstructive hypertrophic cardiomyopathy in the EXPLORER-HCM randomized trial, researchers reported.

As part of the 2022 Year in Review, Cardiology Today compiled a list of selected drugs and devices related to the specialty that were newly approved or cleared. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omissions. Appearance of a drug or device does not constitute any endorsement by Cardiology Today, its editors, publisher or editorial board. – The Editors

Healio and Cardiology Today have curated a list of the top cardiology and cardiac/vascular intervention news reported from meetings in 2022.

The year 2022 was one full of practice-changing advances in cardiology, with new data, drugs and management strategies for everything from HF and hypertension to CVD prevention.

Healio and Cardiology Today have aggregated a list of the top headlines of 2022 in heart failure and transplantation.

Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently misunderstood, and often goes undiagnosed in clinical practice.